{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:49:18Z","timestamp":1776412158051,"version":"3.51.2"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"CorMedix Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guidelines recommend \u22652 weeks of antifungal therapy after candidemia clearance and for invasive candidiasis (IC). This post-hoc analysis evaluates Day 7 pooled data from the phase 2 STRIVE and phase 3 ReSTORE trials to explore early antifungal activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with candidemia and\/or IC received weekly rezafungin 400\/200\u2005mg or daily caspofungin 70\/50\u2005mg for \u22644 weeks. Efficacy was evaluated in the modified intent-to-treat population via all-cause mortality (ACM; primary endpoint; 20% noninferiority margin), mycological eradication, and time to negative blood culture (TTNBC) at days 7, 14, and 30 (TTNBC assessed only in patients with candidemia). Day 7 safety was evaluated in the safety population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Rezafungin was noninferior to caspofungin at each timepoint. Day 7 ACM rates were 7.9% (11\/139) for rezafungin and 5.2% (8\/155) for caspofungin (weighted difference [95% CI]: 3.0% [\u22123.7, 9.7]). Mycological eradication was similar between groups at all timepoints. Day 7 rates were 71.2% (99\/139) and 65.2% (101\/155), respectively (weighted difference [95% CI]: 6.6% [\u22124.0, 17.1]). Median (interquartile range) TTNBC was numerically shorter for rezafungin (22.3 [14.3\u201347.0] hours; caspofungin 26.3 [17.8\u2013112.6] hours). Subgroup analyses suggested potential Day 7 benefits for rezafungin in patients with candidemia or C. albicans. Day 7 safety for rezafungin was consistent with previous reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rezafungin was noninferior to caspofungin in candidemia and\/or IC from Day 7, with shorter TTNBC in patients with candidemia. Subgroup analysis suggested a potential early benefit with rezafungin in some patients. Trials exploring shorter treatment durations for some patients are warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trials registrations<\/jats:title>\n                    <jats:p>NCT02734862 (STRIVE); NCT03667690 (ReSTORE).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag143","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:40:01Z","timestamp":1773924001000},"source":"Crossref","is-referenced-by-count":0,"title":["Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized Trials"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-7589","authenticated-orcid":false,"given":"Luis","family":"Ostrosky-Zeichner","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, McGovern Medical School , Houston, Texas ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-1182","authenticated-orcid":false,"given":"Jalal A","family":"Aram","sequence":"additional","affiliation":[{"name":"CorMedix Therapeutics, Parsippany , New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4469-4345","authenticated-orcid":false,"given":"Mark","family":"Redell","sequence":"additional","affiliation":[{"name":"CorMedix Therapeutics, Parsippany , New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-5750","authenticated-orcid":false,"suffix":"III","given":"George R","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of California Davis Medical Center , Sacramento, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne (Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases [CECAD]; Department I of Internal Medicine, Division of Infectious Diseases, Excellence Center for Medical Mycology [ECMM] and Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf [CIO ABCD]; and Clinical Trials Center Cologne [ZKS K\u00f6ln]) University of Cologne, , Cologne ,","place":["Germany"]},{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne , Cologne ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A","family":"McKinnell","sequence":"additional","affiliation":[{"name":"Torrance Memorial Medical Center , Los Angeles, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7612-4710","authenticated-orcid":false,"given":"Andrej","family":"Spec","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine in St.Louis , St. Louis, Missouri ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G","family":"Pappas","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"2026041703020102900_ofag143-B1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","article-title":"Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project","volume":"23","author":"Bassetti","year":"2019","journal-title":"Crit Care"},{"key":"2026041703020102900_ofag143-B2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/cid\/ciac004","article-title":"Attributable mortality of Candida bloodstream infections in the modern era: a propensity score analysis","volume":"75","author":"Mazi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026041703020102900_ofag143-B3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2026041703020102900_ofag143-B4","doi-asserted-by":"crossref","first-page":"ofac097","DOI":"10.1093\/ofid\/ofac097","article-title":"Economic burden of fungal diseases in the United States","volume":"9","author":"Benedict","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026041703020102900_ofag143-B5","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/cid\/ciy776","article-title":"Estimation of direct healthcare costs of fungal diseases in the United States","volume":"68","author":"Benedict","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026041703020102900_ofag143-B6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vhri.2019.07.002","article-title":"The economic burden of candidemia and invasive candidiasis: a systematic review","volume":"21","author":"Wan Ismail","year":"2020","journal-title":"Value Health Reg Issues"},{"key":"2026041703020102900_ofag143-B7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026041703020102900_ofag143-B8","author":"Mundipharma GmbH"},{"key":"2026041703020102900_ofag143-B9","author":"Melinta Therapeutics LLC"},{"key":"2026041703020102900_ofag143-B10","author":"Mundipharma"},{"key":"2026041703020102900_ofag143-B11"},{"key":"2026041703020102900_ofag143-B12","author":"A phase 2, multicenter, randomized, double-blind study of the safety, tolerability, and efficacy of intravenous CD101 vs intravenous caspofungin followed by oral fluconazole step-down in the treatment of subjects with candidemia and\/or invasive candidiasis","year":"2016"},{"key":"2026041703020102900_ofag143-B13"},{"key":"2026041703020102900_ofag143-B14","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026041703020102900_ofag143-B15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2026041703020102900_ofag143-B16","doi-asserted-by":"crossref","first-page":"e01627-16","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041703020102900_ofag143-B17","doi-asserted-by":"crossref","first-page":"e00758-17","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041703020102900_ofag143-B18","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jac\/dkq081","article-title":"Echinocandin pharmacodynamics: review and clinical implications","volume":"65","author":"Pound","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026041703020102900_ofag143-B19","doi-asserted-by":"crossref","first-page":"107234","DOI":"10.1016\/j.ijid.2024.107234","article-title":"Evaluation of clinical outcomes of anidulafungin for the treatment of candidemia in hospitalized critically ill patients with obesity: a multicenter, retrospective cohort study","volume":"148","author":"Alsowaida","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2026041703020102900_ofag143-B20","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1469-0691.2012.03784.x","article-title":"Anidulafungin for the treatment of candidaemia\/invasive candidiasis in selected critically ill patients","volume":"18","author":"Ruhnke","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026041703020102900_ofag143-B21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026041703020102900_ofag143-B22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026041703020102900_ofag143-B23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13054-024-05117-5","article-title":"Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials","volume":"28","author":"Honore","year":"2024","journal-title":"Crit Care"},{"key":"2026041703020102900_ofag143-B24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026041703020102900_ofag143-B25","doi-asserted-by":"crossref","first-page":"e0091623","DOI":"10.1128\/aac.00916-23","article-title":"Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis","volume":"67","author":"Roepcke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041703020102900_ofag143-B26","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3389\/fmicb.2016.01995","article-title":"Genetic drivers of multidrug resistance in Candida glabrata","volume":"7","author":"Healey","year":"2016","journal-title":"Front Microbiol"},{"key":"2026041703020102900_ofag143-B27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/jof7080667","article-title":"Candida glabrata: pathogenicity and resistance mechanisms for adaptation and survival","volume":"7","author":"Hassan","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2026041703020102900_ofag143-B28","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/jac\/dkx448","article-title":"We can do better: a fresh look at echinocandin dosing","volume":"73","author":"Bader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026041703020102900_ofag143-B29","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1128\/AAC.00620-16","article-title":"Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species","volume":"60","author":"Locke","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041703020102900_ofag143-B30"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag143\/67436966\/ofag143.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/4\/ofag143\/68099274\/ofag143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/4\/ofag143\/68099274\/ofag143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:02:21Z","timestamp":1776409341000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag143\/8530907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag143","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,21]]},"article-number":"ofag143"}}